CTRI/2024/04/065373招募中2 期
A phase II randomised controlled study assessing the role of dose escalation using [18F] FMISO PET CT in head and neck cancer: The DE-HyART (dose escalation using hypoxia-adjusted radiotherapy) protocol. - DE-HyART
Varian Medical Systems Inc0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Performance status: ECOG 0 – 2
- •2.Histology proved – squamous cell carcinoma
- •3.Tumour sites: Oral Cavity, Oropharynx, Hypopharynx and Larynx
- •4.Sufficient bone marrow reserve within the last 14 days.
- •5.Liver functions and kidney functions within normal limits
- •6.Nutritional and dental assessment before inclusion into the study
排除标准
- •1.HPV (p16) positive tumours
- •2.Prior surgery and/or radiation therapy given for any HNC
- •3.T1/T2 Glottic cancer
- •4.Metastatic disease or disease not amenable for definitive locoregional treatment.
- •5.Medical co-morbidity hampering the administration of radiation and/or chemotherapy (cisplatin)
- •6.Pregnancy or lactation
研究者
相似试验
已完成
不适用
An exploratory study of dignity therapy for older people in care homesISRCTN37589515King's College London (UK)64
已完成
2 期
An exploratory study of Dignity Therapy for people with advanced cancerAdvanced cancerMalignant neoplasm of other and ill-defined sitesCancerISRCTN29868352King's College London (UK)40
进行中（未招募）
不适用
Safety and immunogenicity study of GSK Biologicals' malaria vaccine 257049, when incorporated into an EPI regimen.Primary immunization against Plasmodium falciparum malaria in healthy male and female infants aged 6 to 10 weeks at first vaccine dose, if eligible according to inclusion and exclusion criteria.EUCTR2012-005695-34-Outside-EU/EEAGlaxoSmithKline Biologicals511
尚未招募
2 期
The effects of novel medicinal cannabis formulation IHL-42X on apnoea hypopnea index in adults with suspected or diagnosed mild to moderate obstructive sleep apnoea.ACTRN12619001103156Cannvalate30
已完成
2 期
A randomized controlled Phase II study comparing TS-1 alone with CDDP+TS-1 as postoperative adjuvant chemotherapy in non-small-cell-lung-cancer ; translational research of the chemotherapy effect prediction factoron Small Cell Lung CancerJPRN-UMIN000001658West Japan Oncology Group200